Cover Image
市場調查報告書

多發性硬化症治療藥市場產品·開發平台分析

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

出版商 Frost & Sullivan 商品編碼 318889
出版日期 內容資訊 英文 68 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性硬化症治療藥市場產品·開發平台分析 A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market
出版日期: 2014年11月10日 內容資訊: 英文 68 Pages
簡介

目前多發性硬化症多以注射藥為中心。但今後一般認為將朝向口服式的治療藥發展,市場將由注射藥轉換為口服藥。再者多發性硬化症治療藥可配合患者種類,分為復發型、緩解型、二度惡化型、原發惡化型、復發緩解型等。

本報告提供全球的多發性硬化症(MS)治療藥之市場相關分析,提供現在已上市以及臨床實驗後期階段(第三階段)的醫藥品概要·效力,及現在·未來市場趨勢預測,整體市場結構與今後的方向性等調查評估。

第1章 摘要整理

  • 主要的分析結果
  • 近幾年的市場趨勢
  • 今後的醫療趨勢的考察
  • 值得注意的企業

第2章 分析方法·範圍

第3章 簡介

  • 簡介
  • 市場概要和明細

第4章 市場背景情況

  • 主要國家的多發性硬化症(MS)的患病人數
  • 多發性硬化症的治療方法:醫生用指南

第5章 競爭環境

  • 已上市/開發中產品的種數
  • 多發性硬化症(MS)治療藥的市場競爭環境
  • 已上市產品分析
  • 開發平台分析:臨床實驗階段有的產品
  • 產品上市的時間軸
  • 專利失效的時間軸
  • 已上市產品臨床實驗計劃:AUBAGIO(teriflunomide)
  • 已上市產品臨床實驗計劃:Plegridy
  • 已上市產品臨床實驗計劃:Tysabri
  • 已上市產品臨床實驗計劃:Tecfidera
  • 開發中產品臨床實驗計劃:Ocrelizumab,ofatsumumabu
  • 開發中產品臨床實驗計劃:Lemtrada

第6章 已上市/臨床實驗最後階段的產品簡介

  • 產品開發動態即時看板系統:Copaxone
  • 產品開發動態即時看板系統:Avonex(干擾素(interferon)β-1a)
  • 產品開發動態即時看板系統:Betaseron/Extavia(干擾素(interferon)β-1a)
  • 產品開發動態即時看板系統:Rebif(干擾素(interferon)β-1a)
  • 產品開發動態即時看板系統:Tysabri(natalizumab)
  • 產品開發動態即時看板系統:Gilenya
  • 產品開發動態即時看板系統:Tecfidera(口服富馬酸glatiramer)
  • 產品開發動態即時看板系統:Aubagio(teriflunomide)
  • 產品開發動態即時看板系統:Plegridy (BIIB017) (聚乙二醇化干擾素(interferon)β-1a)
  • 產品開發動態即時看板系統:Lemtrada/Campath 1G(alemtuzumab)
  • 產品開發動態即時看板系統:laquinimod
  • 產品開發動態即時看板系統:Zenapax(dakurizumabu)
  • 產品開發動態即時看板系統:Ocrelizumab
  • 產品開發動態即時看板系統:AB1010(mashichinibu)
  • 產品開發動態即時看板系統:ofatsumumabu

第7章 結論與建議

  • 結論與建議
  • 法律上的免責聲明

第8章 關於FROST & SULLIVAN

目錄
Product Code: NEC3-01-00-00-00

Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies

This market insight provides data for the global multiple sclerosis (MS) market. The analysis looks at MS pharmaceutical pipeline drugs that are currently in the market as well as any drugs that are in Phase III trials and pose a potential threat to competitors. It offers a competitive analysis of these drugs and the forecasted outcome and impact of each of these drugs. Injectable drugs dominate MS drugs currently in the market, but the launch of numerous oral pipeline products can shift this market in favor of oral drugs. The MS market is segmented into relapsing, remitting, secondary progressive, primary progressive, and progressive relapsing MS drugs.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Key Findings
  • 2. Recent Market Developments
  • 3. Recent Market Developments (continued)
  • 4. Defining Healthcare Trends in the Future
  • 5. Defining Healthcare Trends in the Future (continued)
  • 6. Companies to Watch

2. METHODOLOGY AND SCOPE

  • 1. Methodology and Scope

3. INTRODUCTION

  • 1. Introduction
  • 2. Market Overview-Segmentation
  • 3. Market Overview-Segmentation (continued)
  • 4. Market Overview-Segmentation (continued)

4. MARKET BACKGROUND

  • 1. Prevalence of MS in Major Market
  • 2. Prevalence of MS in Major Market (continued)
  • 3. Physician Guidelines to MS Therapy

5. COMPETITIVE LANDSCAPE

  • 1. Competitive Landscape-Count of Marketed and Pipeline Products
  • 2. MS Therapeutics Competitive Landscape
  • 3. Marketed Product Analysis
  • 4. Marketed Product Analysis (continued)
  • 5. Pipeline Analysis-Products in Clinical Development
  • 6. Pipeline Analysis-Products in Clinical Development (continued)
  • 7. Pipeline Analysis-Products in Clinical Development (continued)
  • 8. Pipeline Analysis-Products in Clinical Development (continued)
  • 9. Pipeline Analysis-Products in Clinical Development (continued)
  • 10. Pipeline Analysis-Products in Clinical Development (continued)
  • 11. Pipeline Analysis-Products in Clinical Development (continued)
  • 12. Product Launch Timeline
  • 13. Patent Expiration Timeline
  • 14. Marketed Products Clinical Program-AUBAGIO (Teriflunomide)
  • 15. Marketed Products Clinical Program-Plegridy
  • 16. Marketed Products Clinical Program-Tysabri
  • 17. Marketed Products Clinical Program-Tecfidera
  • 18. Pipeline Products Clinical Program-Ocrelizumab, Ofatumumab
  • 19. Pipeline Products Clinical Program-Lemtrada

6. PROFILES OF LAUNCHED AND LATE STAGE INVESTIGATIONAL PRODUCTS

  • 1. Product Dashboard-Copaxone
  • 2. Product Dashboard-Avonex (interferon beta-1a)
  • 3. Product Dashboard-Betaseron/Extavia (interferon beta-1b)
  • 4. Product Dashboard-Rebif (interferon beta-1a)
  • 5. Product Dashboard-Tysabri (natalizumab)
  • 6. Product Dashboard-Gilenya
  • 7. Product Dashboard-Tecfidera (oral Glatiramer Fumarate)
  • 8. Product Dashboard-Aubagio (Teriflunomide)
  • 9. Product Dashboard-Plegridy (BIIB017) (pegylated interferon beta-1a)
  • 10. Product Dashboard-Lemtrada/Campath 1G (Alemtuzumab)
  • 11. Product Dashboard-Laquinimod
  • 12. Product Dashboard-Zenapax (daclizumab)
  • 13. Product Dashboard-Ocrelizumab
  • 14. Product Dashboard-AB1010 (Masitinib)
  • 15. Product Dashboard-Ofatumumab

7. CONCLUSIONS AND RECOMMENDATIONS

  • 1. Conclusions and Recommendations
  • 2. Legal Disclaimer

8. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top